533 related articles for article (PubMed ID: 22406516)
1. Pancreatic ductal adenocarcinoma: a review of immunologic aspects.
Wachsmann MB; Pop LM; Vitetta ES
J Investig Med; 2012 Apr; 60(4):643-63. PubMed ID: 22406516
[TBL] [Abstract][Full Text] [Related]
2. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
3. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Sahin IH; Askan G; Hu ZI; O'Reilly EM
Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
[TBL] [Abstract][Full Text] [Related]
5. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma.
Schmiechen ZC; Stromnes IM
Front Immunol; 2020; 11():613815. PubMed ID: 33584701
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for pancreatic ductal adenocarcinoma.
Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
[TBL] [Abstract][Full Text] [Related]
8. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi M; Bartholin L; Neuzillet C
World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
10. Promising Therapeutic Approach in Pancreatic Cancer: Metabolism-Related Genes.
Choe S; Kwak W; Kim E; Shin S; Shin M; Koh HJ; Yoon H
Front Biosci (Landmark Ed); 2024 Apr; 29(4):137. PubMed ID: 38682209
[TBL] [Abstract][Full Text] [Related]
11. Complex role for the immune system in initiation and progression of pancreatic cancer.
Inman KS; Francis AA; Murray NR
World J Gastroenterol; 2014 Aug; 20(32):11160-81. PubMed ID: 25170202
[TBL] [Abstract][Full Text] [Related]
12. Exploiting inflammation for therapeutic gain in pancreatic cancer.
Steele CW; Jamieson NB; Evans TR; McKay CJ; Sansom OJ; Morton JP; Carter CR
Br J Cancer; 2013 Mar; 108(5):997-1003. PubMed ID: 23385734
[TBL] [Abstract][Full Text] [Related]
13. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
[TBL] [Abstract][Full Text] [Related]
14. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
15. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.
Okubo S; Suzuki T; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Takahashi S; Kojima M
Cancer Sci; 2021 Jul; 112(7):2895-2904. PubMed ID: 33931909
[TBL] [Abstract][Full Text] [Related]
16. Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes.
de Koning W; Latifi D; Li Y; van Eijck CHJ; Stubbs AP; Mustafa DAM
Front Immunol; 2021; 12():649061. PubMed ID: 33986743
[TBL] [Abstract][Full Text] [Related]
17. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
[TBL] [Abstract][Full Text] [Related]
18. Establishment of Slice Cultures as a Tool to Study the Cancer Immune Microenvironment.
Jiang X; Seo YD; Sullivan KM; Pillarisetty VG
Methods Mol Biol; 2019; 1884():283-295. PubMed ID: 30465211
[TBL] [Abstract][Full Text] [Related]
19. Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
Bear AS; Vonderheide RH; O'Hara MH
Cancer Cell; 2020 Dec; 38(6):788-802. PubMed ID: 32946773
[TBL] [Abstract][Full Text] [Related]
20. Restoration of miR-340 controls pancreatic cancer cell
Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]